Dr. Reddy seeks nod for DCGI approval for Phase 3 clinical trials of Sputnik V in India

Dr Reddy’s Laboratories has applied permission to the Drugs Controller General of India (DCGI) for conducting the phase-3 human clinical trials of Sputnik V, Russian coronavirus vaccine against COVID-19 in India, according to the sources.

“Dr Reddy’s Laboratories has applied to the DCGI seeking permission to conduct phase-3 human clinical trials of the Sputnik V vaccine against COVID-19 developed by Russia. The DCGI will carry out a technical evaluation of the application before giving its approval,” according to the sources.

Dr. Reddy has partnered with Russian Direct Investment Fund (RDIF) to conduct clinical trials of Sputnik V as well as its distribution.
Upon regulatory approval in India, RDIF will supply to Dr Reddy’s 100 million doses of the vaccine, the firm said last month.


Please enter your comment!
Please enter your name here